Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pemigatinib

FDA-approved product (tablet, oral), marketed as Pemazyre.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Pemigatinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Cholangiocarcinoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fibroblast growth factor receptor (fgfr) tyrosine kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli56.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pemigatinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pemigatinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

    NCT02924376 · start 2017-01-16

    Registered record
    Registry ID
    NCT02924376
    Conditions
    Cholangiocarcinoma
    Interventions
    Pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-01-16
    Completion
    2022-02-01
    Enrolment
    147

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCholangiocarcinoma
    InterventionPemigatinib
    PhasePhase 2
    Registry statusCompleted

  • A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

    NCT02872714 · start 2017-01-12

    Registered record
    Registry ID
    NCT02872714
    Conditions
    UC (Urothelial Cancer)
    Interventions
    pemigatinib; pemigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-01-12
    Completion
    2022-02-01
    Enrolment
    263

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUC (Urothelial Cancer)
    Interventionpemigatinib; pemigatinib
    PhasePhase 2
    Registry statusCompleted

  • The Drug Rediscovery Protocol (DRUP Trial)

    NCT02925234 · start 2016-08

    Registered record
    Registry ID
    NCT02925234
    Conditions
    Cancer; Tumors; Neoplasm; Neoplasia
    Interventions
    Panitumumab; Olaparib; Dabrafenib; Nilotinib; Trametinib; Erlotinib; Trastuzumab and Pertuzumab (combination treatment); Vemurafenib and Cobimetinib (combination treatment); Vismodegib; Regorafenib; Nivolumab; Afatinib; Dabrafenib and trametinib; Ribociclib; Lenvatinib; Pembrolizumab; Durvalumab; Rucaparib; Axitinib; Palbociclib; Crizotinib; Sunitinib; Cabozantinib; Abemaciclib; Alectinib; Atezolizumab and Bevacizumab; Ipilimumab and nivolumab; Entrectinib; Talazoparib; Dacomitinib; Lorlatinib; Erdafitinib; Alpelisib; Niraparib; Pemigatinib; Selpercatinib; Tepotinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2016-08
    Completion
    2027-12
    Enrolment
    1,550

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer; Tumors; Neoplasm; Neoplasia
    InterventionPanitumumab; Olaparib; Dabrafenib; Nilotinib +33 more
    PhasePhase 2
    Registry statusRecruiting

  • Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

    NCT02393248 · start 2015-02-27

    Registered record
    Registry ID
    NCT02393248
    Conditions
    Lung Cancer; Solid Tumor; Gastric Cancer; Urothelial Cancer; Endometrial Cancer; Multiple Myeloma; Myeloproliferative Neoplasms; Breast Cancer; Cholangiocarcinoma; UC; MPN
    Interventions
    Pemigatinib; Gemcitabine; Pembrolizumab; Docetaxel; Trastuzumab; Retifanlimab; Cisplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2015-02-27
    Completion
    2021-12-17
    Enrolment
    201

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer; Solid Tumor; Gastric Cancer; Urothelial Cancer +7 more
    InterventionPemigatinib; Gemcitabine; Pembrolizumab; Docetaxel +3 more
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic Cancer

    NCT03906357

    Registered record
    Registry ID
    NCT03906357
    Conditions
    Not recorded
    Interventions
    Pemigatinib
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNot recorded
    InterventionPemigatinib
    PhaseNot recorded
    Registry statusNo longer available